title: Effect of recombinant fibroblast interferon and recombinant immune interferon on growth and the antigenic phenotype of multidrug-resistant human glioblastoma multiforme cells.
abstract: To study the effect of drug resistance on the response of stage IV astrocytomas to interferon, a human glioblastoma multiforme cell line, GBM-18, was transfected with an expression-vector plasmid containing a human multidrug resistance (MDR) gene (pHaMDR1/A), and clones surviving in colchicine were isolated. GBM-18 multidrug-resistant subclones displayed cross-resistance to other chemotherapeutic agents, including vincristine, doxorubicin, and dactinomycin. The multidrug-resistant phenotype was reversible when GBM-18 multidrug-resistant cells were cultured in colchicine and the calcium-channel blocker verapamil. The level of the MDR1 gene (also known as PGY1) message was increased in GBM-18 multidrug-resistant cells selected for increased resistance to colchicine, and this effect was not correlated with an amplification of the MDR1 gene. In both parental GBM-18 and GBM-18 multidrug-resistant cells, growth was suppressed to a greater degree when cultures were treated with the combination of fibroblast interferon (IFN-beta) and immune interferon (IFN-gamma). Parental cells and multidrug-resistant subclones varied in their de novo and/or interferon-modulated expression of HLA class I and class II antigens, a high-molecular-weight melanoma-associated antigen, and intercellular adhesion molecule 1 (ICAM-1). Of the antigens tested, ICAM-1 and HLA class I antigens were the most sensitive to enhanced expression induced by IFN-beta and IFN-gamma when used alone or in combination. The results of the present study indicate that multidrug-resistant human glioblastoma multiforme cells retain their increased sensitivity to the antiproliferative activity of the combination of IFN-beta plus IFN-gamma, and differences in antigenic phenotype are apparent in independent multidrug-resistant glioblastoma multiforme clones.
authors.affiliation: Department of Urology, Columbia University, College of Physicians and Surgeons, New York, NY 10032.
authors.forename: P G
authors.initials: PG
authors.lastname: Reddy
authors.forename: G M
authors.initials: GM
authors.lastname: Graham
authors.forename: S
authors.initials: S
authors.lastname: Datta
authors.forename: L
authors.initials: L
authors.lastname: Guarini
authors.forename: T A
authors.initials: TA
authors.lastname: Moulton
authors.forename: H P
authors.initials: HP
authors.lastname: Jiang
authors.forename: M M
authors.initials: MM
authors.lastname: Gottesman
authors.forename: S
authors.initials: S
authors.lastname: Ferrone
authors.forename: P B
authors.initials: PB
authors.lastname: Fisher
mesh_terms: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000235:genetics; D015152:Blotting, Northern; D015139:Blotting, Southern; D002455:Cell Division / Q000187:drug effects; D004351:Drug Resistance / Q000235:genetics; D005909:Glioblastoma / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007370:Interferon Type I / Q000494:pharmacology*; D007371:Interferon-gamma / Q000494:pharmacology*; D010641:Phenotype; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma